{"filings":[{"id":94385,"accession_number":"0001649094-26-000015","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte Q1 net loss $320.6M; OPUS Phase 3 enrollment completed; topline data Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $2.74B as of Mar 31, up from $2.44B Dec 31; includes $601.8M from Feb 2026 equity offering.","Net loss $320.6M for Q1 2026 vs $140.7M in Q1 2025; R&D expenses doubled to $312.8M.","All three VAX-31 adult Phase 3 trials (OPUS-1, OPUS-2, OPUS-3) fully enrolled with 6,191 adults dosed.","Topline OPUS-1 data expected Q4 2026; OPUS-2 and OPUS-3 data expected H1 2027.","VAX-31 infant Phase 2 fully enrolled (900 infants); topline data by end of H1 2027; VAX-A1 Phase 1 start mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106726,"accession_number":"0001649094-26-000005","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte reports 2025 net loss of $766.6M; cash $2.44B plus $600M from Feb equity offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 net loss $766.6M vs $463.9M in 2024; R&D expenses $794.3M (up 67% YoY).","Cash, equivalents, investments $2.44B at Dec 31, 2025; $632.5M gross from Feb 2026 public offering.","VAX-31 adult Phase 3 program (OPUS-1/2/3) underway; topline OPUS-1 data expected Q4 2026, OPUS-2/3 in H1 2027.","VAX-31 infant Phase 2 dose-finding study (900 infants) fully enrolled; data from series and booster expected by H1 2027.","Plan to initiate Phase 1 study for Group A Strep vaccine candidate VAX-A1 in 2026; dedicated Lonza facility completed."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106725,"accession_number":"0001193125-26-067546","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxcyte enters $500M at-the-market equity offering; terminates prior $270.3M ATM with Jefferies","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sales agreement with Leerink Partners for up to $500M in common stock via at-the-market offerings.","Placement agent receives up to 3.00% compensation on gross proceeds from sales.","Terminated prior sales agreement with Jefferies under which $270.3M had been sold.","Company not obligated to sell any shares; no assurance of any sales under new agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106724,"accession_number":"0001193125-26-033578","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2026-02-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxcyte raises $600.2M in public offering of 12.65M shares at $50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 11M shares at $50.00 public price; underwriter option for 1.65M shares exercised.","Net proceeds of approximately $600.2M after underwriting discounts and expenses.","Underwriters purchased shares at $47.50 each; offering closed on February 2, 2026.","Proceeds will support general corporate purposes, including pipeline development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123042,"accession_number":"0001649094-25-000116","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Vaxcyte boosts severance multipliers for CEO Pickering and three other execs effective Dec 31, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Pickering: base salary severance multiplier for Qualifying Termination increases to 1.5x (from 1.0x); CIC termination to 2.0x (from 1.5x).","CFO Guggenhime, COO Wassil, CTOO Dhaliwal: non-CIC multiplier rises to 1.0x (from 0.75x/0.5x); CIC to 1.5x (from 1.0x/0.75x).","COBRA severance multipliers increased proportionally across all four executives.","Changes effective Dec 31, 2025, approved by Compensation Committee to align with peer group levels."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123041,"accession_number":"0001649094-25-000112","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte Q3 net loss $212.8M; cash $2.67B; VAX-31 adult pivotal study start Dec 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $212.8M for Q3 2025 vs $103.1M in Q3 2024; R&D expenses $209.9M, up from $116.9M.","Cash, cash equivalents and investments $2.67B as of Sept 30, 2025, expected to fund operations into mid-2028.","Final VAX-24 infant Phase 2 data show robust dose-dependent immune responses, validating higher VAX-31 doses.","VAX-31 adult pivotal non-inferiority study to start Dec 2025; topline data expected in 2026.","Up to $1B fill-finish agreement with Thermo Fisher in North Carolina for long-term U.S. commercial supply."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139741,"accession_number":"0001649094-25-000102","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-09-30T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Vaxcyte signs 15-year manufacturing deal with Thermo Fisher's Patheon","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement covers formulation, fill, finish, testing at Patheon's Greenville, NC facility.","Binding minimum purchase commitments; termination fee in mid-eight-figures for convenience.","Initial 15-year term with auto-renewal; includes tech transfer and capex reimbursement.","Customary termination rights for cause, regulatory breach, or insolvency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139740,"accession_number":"0001649094-25-000096","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte Q2 net loss $166.6M, cash $2.83B; VAX-31 Phase 3 on track for Q4 start","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $166.6M for Q2 2025 vs $128.7M a year ago; R&D expenses $194.2M, up from $131.5M.","Cash, cash equivalents and investments $2.83B as of June 30, 2025; cash runway extended to mid-2028.","VAX-31 adult pivotal non-inferiority study to begin Q4 2025 with topline data expected in 2026.","VAX-31 infant Phase 2 modified: new optimized dose arm added, low dose arm discontinued; data by H1 2027.","Early pipeline streamlined: paused VAX-A1 and VAX-GI, discontinued VAX-PG due to insufficient efficacy."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157298,"accession_number":"0001649094-25-000084","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vaxcyte shareholders re-elect all three Class II directors and approve officer exculpation","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["John Furey reelected with 120.7M For vs 0.4M Withheld; Jacks Lee 107.3M For vs 13.8M Withheld.","Heath Lukatch, Ph.D. reelected with 99.2M For vs 21.9M Withheld.","Deloitte & Touche ratified as auditor for FY2025 with 124.8M For, 0.2M Against.","Advisory say-on-pay passed with 77.1M For, 44.0M Against, 4.0M broker non-votes.","Amendment to certificate for officer exculpation approved with 112.3M For, 8.8M Against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157297,"accession_number":"0001649094-25-000073","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte Q1 net loss $140.7M; VAX-24 infant data positive, VAX-31 Phase 3 set for mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $140.7M vs $95.0M YoY; cash, equivalents & investments $2.95B at March 31, 2025.","VAX-24 infant Phase 2 met non-inferiority criteria for 20 of 24 serotypes; robust OPA responses.","VAX-31 infant Phase 2 advanced to second stage; adult Phase 3 non-inferiority study to start mid-2025.","New third-generation PCV candidate VAX-XL announced to further expand serotype coverage.","Dr. Olivier Brandicourt (ex-Sanofi CEO) appointed to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157296,"accession_number":"0001649094-25-000057","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vaxcyte appoints Dr. Olivier Brandicourt to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointment effective May 1, 2025 as a Class III director with term expiring at 2026 annual meeting.","Board determined Dr. Brandicourt qualifies as independent under Nasdaq rules.","Receives initial equity award of $800,000 in nonstatutory stock options vesting over 36 months.","Annual cash retainer of $50,000 and annual equity award of $450,000 (75% option, 25% RSU).","Standard indemnification agreement entered; no reportable transactions per Item 404(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175685,"accession_number":"0001193125-25-067901","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vaxcyte reports positive VAX-24 infant Phase 2 topline; selects mid dose; announces VAX-XL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VAX-24 well-tolerated; safety similar to Prevnar 20; no related serious adverse events.","Mid dose (2.2mcg) met non-inferiority criteria on seroconversion for 20 of 24 serotypes; dose-dependent responses with little carrier suppression.","Four VAX-24-unique serotypes met all target criteria at all doses evaluated.","Company selects mid dose for optimized formulation; plans infant Phase 3 with VAX-24 or VAX-31 pending VAX-31 data (mid-2026).","Announces VAX-XL, third-generation PCV candidate designed to provide broadest coverage PCV in development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175684,"accession_number":"0001649094-25-000027","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte reports Q4 2024 net loss of $137.1M; cash $3.13B; VAX-31 Phase 3 on track for mid-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2024: $137.1M; full year 2024: $463.9M vs $402.3M in 2023.","Cash, cash equivalents and investments: $3.13B at Dec 31, 2024, up from $1.24B a year ago.","R&D expenses $133.6M in Q4; $476.6M for full year on increased PCV program activities.","VAX-31 adult Phase 3 pivotal study expected to start by mid-2025 with topline data in 2026.","VAX-24 infant Phase 2 primary immunization topline data expected by end of Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192630,"accession_number":"0001193125-24-263406","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-11-21T23:59:59+00:00","items":["1.01","8.01"],"status":"ready","headline":"Vaxcyte amends HQ lease to 258,581 RSF, subleases 16,731 SF to Iovance Biotherapeutics","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended lease expands premises from ~113k to 258,581 RSF across floors 1-6, phased move-ins Feb 2025 through June 2026.","Initial base rent $5.941-$6.026/RSF/month for existing premises; $6.00/RSF for additional; 8-month abatement, 3% annual escalations.","Lease term 120 months from first additional premises commencement, with two 5-year renewal options.","Subleased 16,731 RSF of Suite 100A to Iovance Biotherapeutics for 2 years at $5.95/RSF, rising to $6.1285/RSF after year one.","Security deposit of ~$1.09M in letters of credit carried over from prior leases."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192629,"accession_number":"0001649094-24-000096","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte reports Q3 net loss $103M; cash $3.27B after $1.4B follow-on","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $103.1M for Q3 2024 vs $92.7M in Q3 2023.","Cash, equivalents and investments $3,273M as of Sep 30, 2024, up from $1,243M at Dec 31, 2023.","VAX-31 Phase 1/2 topline positive: met non-inferiority vs PCV20 for all 20 shared serotypes at middle/high doses.","VAX-31 selected for Phase 3 adult program; pivotal non-inferiority study initiation expected by mid-2025.","VAX-24 infant Phase 2 primary series topline data expected by end of Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209079,"accession_number":"0001193125-24-214711","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Vaxcyte raises $1.42B in underwritten public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 10,194,175 shares at $103.00/share and pre-funded warrants to purchase 2,427,184 shares at $102.999/warrant.","Underwriters' 30-day option for additional 1,893,203 shares exercised in full.","Net proceeds expected to be approximately $1.42 billion after discounts and expenses.","Closing expected on or about September 6, 2024, subject to customary conditions.","Offering made under effective shelf registration statement (Form S-3)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209078,"accession_number":"0001193125-24-211572","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Vaxcyte reports positive Phase 1/2 data for VAX-31; all serotypes meet immunogenicity criteria","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VAX-31 showed robust OPA responses for all 31 serotypes at all doses; safety profile similar to Prevnar20.","At high and middle doses, VAX-31 met or exceeded non-inferiority criteria for all 20 serotypes common with PCV20.","For 11 unique serotypes, all three doses met superiority criteria.","Company selects VAX-31 for adult Phase 3; plans to initiate pivotal study by mid-2025 with topline data in 2026.","Also plans VAX-31 infant Phase 2 study in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209077,"accession_number":"0001649094-24-000051","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte Q2 net loss $128.7M; cash $1.85B; VAX-31 adult data due Sept 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $128.7M for Q2 2024 vs $68.3M in Q2 2023; R&D expenses $131.5M, up from $72.7M.","Cash, cash equivalents and investments $1,851.9M as of June 30, 2024, up from $1,242.9M at Dec 31, 2023.","VAX-31 adult Phase 1/2 topline safety and immunogenicity data expected in September 2024; will then select VAX-24 or VAX-31 for Phase 3.","VAX-24 infant Phase 2 topline from primary series due by end of Q1 2025; booster data by end of 2025.","Appointed John Furey to Board; received $9.5M NIAID grant for Chlamydia vaccine program."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209076,"accession_number":"0001193125-24-174317","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Vaxcyte appoints John P. Furey to Board of Directors, effective July 2, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John P. Furey appointed as Class II director; term expires at 2025 annual meeting.","Furey received initial stock option valued at $800,000 vested over 36 months; also joins Compensation Committee.","Annual equity awards of $450,000 (75% option, 25% RSU) and cash retainers of $50,000 board / $7,500 committee.","Indemnification agreement executed; Furey qualifies as independent director under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226924,"accession_number":"0001193125-24-158355","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Vaxcyte shareholders re-elect Class I directors, ratify Deloitte as auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annie Drapeau re-elected with 82,886,170 votes for; Teri Loxam with 96,840,846; Carlos Paya with 96,685,408.","Ratification of Deloitte & Touche as auditor for FY 2024: 103,807,993 for, 14,745 against, 24,027 abstain.","Non-binding advisory vote on executive compensation approved: 91,072,269 for, 7,934,248 against, 23,235 abstain.","Three Class I directors to serve until 2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226923,"accession_number":"0001628280-24-021665","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte reports Q1 net loss $95M, cash $1.9B; VAX-31/24 enrollment complete","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $1.9B at March 31, 2024, up from $1.24B at Dec 31, 2023, including $816.5M net from Feb offering.","Net loss $95.0M vs $60.5M in Q1 2023; R&D expenses rose to $94.6M from $58.1M.","VAX-31 adult Ph1/2 enrollment completed; topline safety/immunogenicity data expected Q3 2024.","VAX-24 infant Ph2 enrollment completed; topline data from primary series expected by end Q1 2025.","Plan to advance either VAX-24 or VAX-31 to adult Ph3 after VAX-31 data; if VAX-24, Ph3 start H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245871,"accession_number":"0000950170-24-021081","cik":1649094,"company_name":"Vaxcyte, Inc.","ticker":"PCVX","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Vaxcyte FY23 net loss $402M; VAX-31 adult Phase 1/2 topline data Q3 2024; cash $1.24B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $402.3M for FY2023 (vs $223.5M in FY2022); cash, equivalents & investments $1.24B as of Dec 31, 2023.","VAX-31 adult Phase 1/2 study enrollment complete; topline safety, tolerability & immunogenicity data expected Q3 2024.","VAX-24 adult program Phase 3-ready following End-of-Phase 2 FDA meeting; either VAX-24 or VAX-31 to advance after VAX-31 readout.","VAX-24 infant Phase 2 enrollment nearing completion; topline data from primary series by end Q1 2025, booster by end 2025.","R&D expenses $332.3M for FY2023, up 96% YoY due to manufacturing scale-up for PCV programs."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":7341178616.598196,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}